Encouraging results in one male subgroup may guide future clinical practice.
Vienna, Austria, Friday 16 April: Results of a German study1 presented today at the International Liver Congress™ 2010, the annual meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver2.
Download the full press release below.
